LivaNova PLC
As of Oct 22, 2026, LivaNova is in Stage 3, the topping phase, now in week 6 (since Sep 17, 2026). It closed at $81.27, 4.8% below its 52-week high and above its 200-day average, which is rising.
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LIVN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LIVN among Medical Devices17th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …17 | LIVN | Stage 3 · wk 6 | 85 | +5.3% |
LivaNova: quick answers
What stage is LivaNova in?
As of Oct 22, 2026, LivaNova (LIVN) is in Stage 3, the topping phase. It entered Stage 3 on Sep 17, 2026 and is in week 6. What the four stages mean
Is LivaNova in an uptrend?
Its uptrend has stalled. LivaNova is in Stage 3, the topping phase that follows an advance. It trades 12.3% above its 200-day average, which is rising.
How far is LivaNova from its 52-week high?
LivaNova closed at $81.27 on Oct 22, 2026, 4.8% below its 52-week high of $85.33. Its 52-week low is $49.57.
How has LivaNova performed over the past year?
As of Oct 22, 2026, LivaNova is up 48.5% over the past year and up 34.0% so far in 2026.
Which sector and industry is LivaNova in?
LivaNova is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.